TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30032885
Drug: Ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.5 mg kg‐1
Study: 30032885
Drug: Ketamine 1
Normalized name: ketamine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 1 mg kg‐1
Study: 26867863
Drug: Real-time medication
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Real-time medication monitoring (medication dispenser for ribavirin intake)
Study: 26867863
Drug: Real-time medication
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Real-time medication monitoring
Study: 26867863
Drug: Real-time medication
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Real-time medication monitoring and standard-of-care
Study: 22729797
Drug: Cognitively oriented
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitively oriented behavioural rehabilitation in combination with Qigong
Study: 15705369
Drug: GnRH-antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH-antagonist
Study: 10596247
Drug: Ego‐Oriented Individual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ego‐Oriented Individual Therapy (EOIT)
Study: 8695600
Drug: Resistant starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistant starch from potato (17-30 g/d)
Study: 8695600
Drug: Resistant starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistant starch from banana (17-30 g/d)
Study: 8695600
Drug: Resistant starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistant starch from wheat (17-30 g/d)
Study: 8695600
Drug: Resistant starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistant starch from maize (17-30 g/d)
Study: 8695600
Drug: Bran NSP
Normalized name: bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bran NSP (18.4 g NSP from bran/d)
Study: 1917046
Drug: Intravenous penicillin
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous penicillin G sodium (PG) 400,000‐500,000 I.U./kg/day for 14 days
Study: 1917046
Drug: Intravenous ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ceftriaxone 75‐93 mg/kg/day for 14 days
Study: 6627213
Drug: Crossover therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover therapy (Adriamycin)
Study: 29920736
Drug: Mirogabalin 15
Normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Mirogabalin 15 mg + Probenecid 500 mg every 6 h from days 1 to 4
Study: 29920736
Drug: Mirogabalin 15
Normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Mirogabalin 15 mg + Cimetidine 400 mg every 6 h from days 1 to 4
Study: 29920736
Drug: Mirogabalin 15
Normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Mirogabalin 15 mg alone
Study: 27422406
Drug: CFNB/SAMO group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CFNB/SAMO group (continuous femoral nerve block with mini-dose spinal morphine)
Study: 24814858
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (5mg daily) and vitamin B12 (500 μg twice daily) for 12 weeks
Study: 22574583
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine treatment group (Chinese medicine placebo, Western medicine, and rehabilitation)
Study: 22574583
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Chinese medicine placebo and rehabilitation)
Study: 21344827
Drug: Oral-B Pulsonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-B Pulsonic sonic toothbrush
Study: 11777104
Drug: All conditions
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All conditions (High-standardization CBT, Low-standardization CBT, Treatment as usual)
Study: 9610341
Drug: Iloprost low
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost low dose (LD) 100 micrograms bid for 8 weeks
Study: 9610341
Drug: Iloprost high
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost high dose (HD) 200 micrograms bid for 8 weeks
Study: 9610341
Drug: Iloprost low
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost low dose (LD) and high dose (HD)
Study: 7923253
Drug: rt-PA administered
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rt-PA administered within 6 to 24 hours after onset of symptoms
Study: 7923253
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no thrombolytic agent)
Study: 3288479
Drug: Low-dose bromocriptine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose bromocriptine
Study: 4627050
Drug: Continuous intragastric
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intragastric milk feeds (60 ml/kg/24 hr to 300 ml/kg/24 hr over 9 days) using either expressed human breast milk or SMA-S26.
Study: 4627050
Drug: Half-cream Regal
Normalized name: Consolida regalis flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-cream Regal milk (partly-skimmed evaporated cows' milk)
Study: 23019303
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (TU) 1000 mg i.m. injection followed by 500 mg injection every 6 weeks
Study: 23019303
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (TU) + levonorgestrel (LNG) 250 μg orally daily
Study: 23019303
Drug: Testosterone treatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone treatment in cynomolgus monkeys
Study: 15961567
Drug: Early headgear
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early headgear (HG) treatment
Study: 17349681
Drug: Fluticasone (88
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone (88 microg, 2 puffs twice daily)
Study: 15072107
Drug: Carbamazepine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (600 mg/day)
Study: 15072107
Drug: Valproate (1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valproate (1250 mg/day)
Study: 11511432
Drug: Tezosentan (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezosentan (5, 20, 50, 100 mg h(−1))
Study: 9062499
Drug: Once weekly
Normalized name: Actonel 35 4-Week Once Weekly Dosepack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly T4 therapy (7 times the normal daily dose)
Study: 3518556
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg aerosolized verapamil
Study: 3518556
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg aerosolized verapamil
Study: 27567447
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of stimulant medication
Study: 25176015
Drug: LCZ696 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 (200 mg twice daily)
Study: 20695686
Drug: Oral caffeine
Normalized name: caffeine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral caffeine (250 mg/70 kg)
Study: 17968001
Drug: 1 drug
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drug administered at bedtime
Study: 17968001
Drug: All drugs
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All drugs taken on awakening
Study: 16970086
Drug: Fuzheng Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuzheng Capsule (FC) and Quxie Capsule (QC)
Study: 12936975
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of posaconazole oral tablets (50 to 1200 mg)
Study: 12936975
Drug: Posaconazole oral
Normalized name: posaconazole Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole oral tablets (50 to 400 mg) twice daily for 14 days
Study: 12936975
Drug: Posaconazole (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posaconazole (all doses)
Study: 3555042
Drug: Cefotaxime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (2 g three times daily)
Study: 29406427
Drug: AR-L (aerobic
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR-L (aerobic before low-intensity resistance training)
Study: 29406427
Drug: RA-L (aerobic
Approvals — FDA: no, EMA: no, PMDA: no
Description: RA-L (aerobic after low-intensity resistance training)
Study: 19574172
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate 500 mg twice daily for 3 months
Study: 9449270
Drug: grepafloxacin 400
Normalized name: grepafloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: grepafloxacin 400 mg once daily
Study: 9449270
Drug: grepafloxacin 600
Normalized name: grepafloxacin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: grepafloxacin 600 mg once daily
Study: 28988687
Drug: Orantinib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orantinib (200 mg, twice per day)
Study: 26646462
Drug: Goal-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed therapy group (n = 62)
Study: 26646462
Drug: Goal-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed therapy (meta-analysis)
Study: 25937837
Drug: 8.0 mg
Normalized name: KAOLIN 8.0 mg in 100 mL ORAL LIQUID [Diarrhea Control]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8.0 mg oral melatonin nightly for 10 weeks
Study: 20124733
Drug: SCH530348 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH530348 (20 or 40 mg loading dose followed by 1 mg/d or 2.5 mg/d for 60 days)
Study: 20124733
Drug: Standard-of-care (aspirin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care (aspirin, ticlopidine, and heparin)
Study: 19035150
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (blood glucose control at 4.4 to 6.1 mmol/L)
Study: 19035150
Drug: Conventional group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional group (blood glucose control at 10.0 to 11.1 mmol/L)
Study: 17235728
Drug: ACE chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE chemotherapy (doxorubicin 40 mg/m², cyclophosphamide 1000 mg/m², etoposide 120 mg/m² on day 1 IV, plus oral etoposide 240 mg/m² daily on days 2-3) with pegfilgrastim 6 mg by subcutaneous injection on day 4 of each cycle
Study: 8851907
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (BIC) 0.3 g.kg body mass‐1
Study: 8851907
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate (CIT) 0.5 g.kg body mass‐1
Study: 8851907
Drug: Placebo (PLC,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLC, wheat flour, 0.5 g.kg body mass‐1)
Study: 30580266
Drug: goserelin 3.6 mg/28
Approvals — FDA: no, EMA: no, PMDA: no
Description: goserelin 3.6 mg/28 days by subcutaneous injection plus oral anastrozole 1 mg/day for 12 weeks
Study: 30580266
Drug: oral tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tamoxifen 20 mg/day for 12 weeks
Study: 25175762
Drug: Purple grape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purple grape juice (pGJ), 6 ounces twice daily for 4 weeks
Study: 25175762
Drug: Clear apple
Normalized name: Ensure Clear Apple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clear apple juice (cAJ), 6 ounces twice daily for 4 weeks
Study: 20590748
Drug: Pioglitazone 30
Normalized name: pioglitazone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 30 mg od for 12 weeks
Study: 12088161
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg/day, increased to a maximum of 60 mg/day after week 2)
Study: 10438710
Drug: Protocol II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol II (early reinduction treatment) for SRG patients
Study: 10438710
Drug: No early
Approvals — FDA: no, EMA: no, PMDA: no
Description: No early reinduction treatment for SRG patients
Study: 10438710
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (DCLSG ALL-7)
Study: 10438710
Drug: Overall CNS
Normalized name: CN-105
DrugBank: CN-105 (DB18345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall CNS prophylaxis (systemic high-dose methotrexate and intrathecal chemotherapy)
Study: 2111126
Drug: Glucan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucan (50 mg/m2, intravenously daily for 7 days)
Study: 2111126
Drug: Placebo (intravenously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intravenously daily for 7 days)
Study: 28786993
Drug: Uric acid
Normalized name: Uric acid
DrugBank: Uric acid (DB08844)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uric acid administration
Study: 28786993
Drug: Rasburicase administration
Normalized name: Rasburicase
DrugBank: Rasburicase (DB00049)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rasburicase administration
Study: 26536700
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of parecoxib sodium 40 mg after surgery, continued with 40 mg injections after 12, 24, and 36 hours.
Study: 26536700
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg tramadol after surgery, replacing parecoxib sodium in group C.
Study: 22859618
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (450 ml daily for 4 weeks)
Study: 22859618
Drug: De‐alcoholized red
Approvals — FDA: no, EMA: no, PMDA: no
Description: De‐alcoholized red wine (450 ml daily for 4 weeks)
Study: 19191781
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel treatment
Study: 19191781
Drug: Every 3
Normalized name: Eligard Every 3 Months 22.5 MG per 0.375 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every 3 weeks paclitaxel treatment
Study: 10857142
Drug: Terazosin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin (5 mg per day in single dose)
Study: 10857142
Drug: Alfuzosin (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin (7.5 mg per day in 3 doses)
Study: 9358213
Drug: 5-FU monotherapy
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU monotherapy (600 mg/m2)
Study: 9358213
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 5-FU (600 or 400 mg/m2) and high-dose FA (400 mg/m2)
Study: 8257226
Drug: Neostigmine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (0.5 mg)
Study: 25403253
Drug: Subacromial injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subacromial injection therapy (Betamethasone plus prilocaine)
Study: 25202858
Drug: Prophylactic administration
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic administration of fresh frozen plasma (FFP)
Study: 19384779
Drug: IOL optic
Normalized name: Opti-Nail
Approvals — FDA: no, EMA: no, PMDA: no
Description: IOL optic captured behind the posterior capsule with posterior capsulotomy (group 1)
Study: 12148300
Drug: Bupivacain 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacain 0.5% (4 ml) injected retrobulbarly before surgery (group I)
Study: 12148300
Drug: Bupivacain 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacain 0.5% (4 ml) injected retrobulbarly after surgery (group II)
Study: 9586589
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy with selective, long‐acting, alpha1‐blocking agents (terazosin, doxazosin, tamsulosin)
Study: 9586589
Drug: Finasteride (5‐alpha‐reductase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (5‐alpha‐reductase inhibitor)
Study: 9586589
Drug: Device therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Device therapies (Laser prostatectomy including VLAP, TUEP, TILP)
Study: 9586589
Drug: Medical and
Normalized name: allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen Medicated Patch [Stratagraft]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical and device therapies
Study: 7862899
Drug: Ethanol (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.8 ml/kg body weight)
Study: 7862899
Drug: Alcohol treatments
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol treatments
Study: 2536911
Drug: MAC chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAC chemotherapy (methotrexate, dactinomycin, and chlorambucil)
Study: 17947605
Drug: Enteral formula
Normalized name: Standard enteral formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral formula containing 50 g of saccharides enriched with 2.3 g of fiber/100 mL
Study: 17947605
Drug: Enteral formula
Normalized name: Standard enteral formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral formula containing 50 g of saccharides
Study: 9621141
Drug: Recombinant IFN-beta
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recombinant IFN-beta (0.15 x 10(6) IU/g) applied 5 times daily for 4 weeks
Study: 9621141
Drug: Recombinant IFN-beta
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recombinant IFN-beta (1.0 x 10(6) IU/g) applied 5 times daily for 4 weeks
Study: 9621141
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel applied 5 times daily for 4 weeks
Study: 7633951
Drug: Human leukocyte
Normalized name: Human leukocyte antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human leukocyte interferon-alpha cream (2 x 10(6) IU/g) applied three times daily for 5 consecutive days
Study: 7633951
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied three times daily for 5 consecutive days
Study: 7633951
Drug: Human leukocyte
Normalized name: Human leukocyte antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human leukocyte interferon-alpha cream
Study: 330080
Drug: Sulindac given
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulindac given twice daily (100 to 300 mg daily, adjusted according to patient response)
Study: 330080
Drug: Sulindac given
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulindac given 4 times daily (100 to 300 mg daily, adjusted according to patient response)
Study: 26321524
Drug: Yupingfeng granules,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yupingfeng granules, 10 g/time, tid for 2 courses
Study: 26321524
Drug: Synchronous radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synchronous radiotherapy and chemotherapy (Control)
Study: 21519814
Drug: 4-week schedule
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week schedule of gemcitabine (1000 mg/m² as a 30-min infusion weekly for 3 consecutive weeks every 4 weeks)
Study: 21519814
Drug: 3-week schedule
Normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-week schedule of gemcitabine (1000 mg/m² as a 30-min infusion weekly for 2 consecutive weeks every 3 weeks)
Study: 16549639
Drug: Total homocysteine
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total homocysteine (tHcy) measured in tertiles (<14.7, 14.7 to 19.5, > or =19.6 micromol/L)
Study: 12131319
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin substitution
Study: 9817273
Drug: 500 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/m2 amifostine intravenously before HD-RIT
Study: 17390690
Drug: Physiologic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiologic saline solution (Control)
Study: 28079825
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg/kg administered at loss of eyelash reflex (Control group C; n=45)
Study: 28079825
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg/kg administered when BIS fell to less than 40 (Experimental group T; n=45)
Study: 28079825
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg/kg administered when BIS fell below 40 after manual ventilation with sevoflurane (Experimental group S; n=45)
Study: 11685593
Drug: 7 days'
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days' intravenous antibiotics (group A)
Study: 11685593
Drug: 3 days'
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 days' intravenous antibiotics (group B)
Study: 8186347
Drug: Famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 40 mg/day for 3 days
Study: 8186347
Drug: No-drug control
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-drug control period
Study: 3369330
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections with strict surveillance of alcohol intake
Study: 3369330
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections without surveillance
Study: 3369330
Drug: No placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: No placebo injections with surveillance
Study: 3369330
Drug: No placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: No placebo injections without surveillance
Study: 30550515
Drug: BLmax ≥8
Approvals — FDA: no, EMA: no, PMDA: no
Description: BLmax ≥8 mmol·L
Study: 26348533
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of olodaterol (0.5-25 μg)